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People of East Asian ethnicity have a different prevalence of and show unique
clinical characteristics and tumor histology of oncogenic mutations. However,
only limited studies have explored the landscape of genomic alterations in lung
adenocarcinoma derived from Asian patients thus far. In this single-center study,
with an aim to elucidate the mutational profile of lung cancer in people of Chi-
nese ethnicity and to use the obtained information to guide decision-making for
treatment, we employed a well-validated assay to perform comprehensive geno-
mic characterization of tumor specimens from 306 Chinese lung cancer patients.
A total of 845 individual genomic alterations were found in 145 tumor-related
genes with a median of 2.8 alterations (range: 1–18) per sample. The most fre-
quently mutated genes were EGFR (46.7%), TP53 (21.2%), ALK (12.1%; 8.8% of
mutation and 3.3% of rearrangement) and KRAS (10.1%). Upon comparison with
the Cancer Genome Atlas dataset, we found that EGFR was mutated at a much
higher frequency in our cohort than in Caucasians, whereas KRAS was only found
in 10.1% of our Chinese patients. Clinically relevant genomic alterations were
identified in 185 (60.5%) patients, including 50% in adenocarcinoma patients and
14% in squamous cell carcinoma patients. Our findings suggest that the Asian
ethnicity is significantly different from the Caucasian ethnicity with regard to the
presence of somatic driver mutations. Furthermore, we showed that the use of a
comprehensive genotyping approach could help identify actionable genomic
alterations that have potential impact on therapeutic decisions.
T he development of targeted therapy has dramatically chan-ged the treatment modalities for non-small-cell lung cancer
(NSCLC) in specific genotypic subsets of patients.(1) The most
recent version of the National Comprehensive Cancer Network
(NCCN) guidelines for NSCLC recommends that in addition
to the routine testing conducted for EGFR, KRAS and ALK,
tests should also be conducted for BRAF and ERBB2
mutations, MET amplifications and exon 14 skipping muta-
tions, and gene rearrangements involving ROS1 and RET.(2)
Given the increasing availability of various targeted therapies,
combined with the maturity of new technologies, comprehen-
sive genomic profiling (CGP) of lung cancer is rapidly becom-
ing an important trend in cancer pathology diagnosis.(3–6)
Comprehensive information regarding tumor-specific molecular
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abnormalities is valuable in choosing suitable treatment
options to maximize therapeutic benefitsand minimize therapy-
associated risks.(7–9) Moreover, comprehensive analysis of
mutations in oncogenes and key cancer pathways is necessary
to understand the molecular basis of drug resistance and to
modify treatment options accordingly.(10) Finally, detailed pro-
filing of these aberrations in tumors will improve our under-
standing of the genetic basis of diseases and aid in
prognostication.(11–13)
Previous studies have confirmed the feasibility of routine
multiplex genotyping in patients with lung adenocarcinomas
(ADC) for selecting matched therapies and trials.(14–16) Many
patients could become eligible for targeted therapy due to the
discovery of clinically actionable genomic alterations via next
generation sequencing (NGS)-based assays.(17,18) More impor-
tantly, it has been found that individuals with an actionable
driver receiving matched target agents show an obvious
improvement in median survival over those who do not receive
targeted therapy.(19–21) However, most of these previous stud-
ies have focused on tumor samples from Caucasian popula-
tions. It is well known that people of Asian ethnicity have a
different prevalence of and show unique clinical characteristics
and tumor histology of oncogenic mutations.(22) One example
is that female never-smokers of Asian ethnicity show a higher
frequency of EGFR mutation than Caucasian female never-
smokers.(23,24) Therefore, there is a clear need for a more
comprehensive profiling of oncogenic mutations in the Asian
population to guide diagnosis and therapies for lung cancer in
patients of this ethnicity. In this study, we used a well-vali-
dated assay to perform comprehensive genomic profiling on
tumor specimens from 306 Chinese lung cancer patients with
the aim to elucidate the mutational profile of NSCLC in people
of Chinese ethnicity and to use the obtained information to
guide decision-making during treatment.
Materials and Methods
Patients and samples. Formalin-fixed paraffin-embedded
(FFPE) specimens were obtained from 306 Chinese patients
with lung cancer who underwent either surgical resection or
biopsy from June 2016 to December 2016 at the First Affili-
ated Hospital of Guangzhou Medical University. The speci-
mens were independently reviewed by two pathologists to
confirm the histological subtype and tumor cell content. Other
relevant clinical and pathological information, including smok-
ing history, were also collected. The present study was
approved by the Institutional Review Board of the First Affili-
ated Hospital of Guangzhou Medical University. All the
patients who participated in this study provided written
informed consent. All the molecular tests were conducted in
accredited clinical genetics laboratories.
Histological analysis. The pathologic records of the specimens
and all available HE-stained tissue sections, in addition to any
available sections with special stains or immunohistochemical
analysis, were reviewed. Pathological information was collected,
including maximum tumor sizes (in cm) and pathologic disease
stages (p-stage). Staging was based on the guidelines of the 7th
edition of the TNM classification for lung cancer. All the avail-
able HE-stained sections, for each case, were examined by two
pathologists. Histological classification was according to the
IASLC/ATS/ERS classification of lung ADC; each histologic
component present was recorded in 5% increments. The tumors
were classified as ADC in situ (AIS), minimally invasive ADC
(MIA), and invasive ADC, which were further classified into
lepidic predominant, papillary predominant, acinar predominant,
solid predominant, micropapillary predominant, invasive muci-
nous ADC (IMA), and others, according to the predominant his-
tologic component. The amount of lepidic growth and
assessment of the presence or absence of stromal, lymphovascu-
lar space and pleural invasion are the important factors in the
diagnosis of AIS, MIA and invasive ADC.
Next generation sequencing-based genomic profiling. The
specimens were reviewed to ensure tissue adequacy (>20%
tumor nuclei) before testing. DNA was extracted from
unstrained FFPE resections using the QIAamp DNA FFPE Tis-
sue Kit following the manufacturer’s instructions (Qiagen, Hil-
den, Germany). DNA concentration was measured using a
Qubit fluorometer (Thermo Fisher, Waltham, MA, USA). A
targeted next-generation sequencing method was used to iden-
tify the clinically relevant mutation profiles as described previ-
ously.(25) Briefly, FFPE DNA was used for library
construction. Hybridization capture of 13 introns and 436 ex-
ons from 145 cancer-related genes (Table S1), including recur-
rent rearrangement and amplification, was performed. The
hybrid capture libraries were then sequenced to >5009 average
unique coverage using Ion Proton Sequencers (Thermo Fisher).
Sequencing data were processed using a customized bioinfor-
matics pipeline named Otype, which was designed to simulta-
neously detect single nucleotide variations (SNV), short
insertions and deletions (InDels), copy number variations
(CNV) and gene rearrangements. Finally, data interpretation
was focused on genomic alterations associated with clinically
available targeted treatment options according to the standards
and guidelines of the NCCN, the Association for Molecular
Pathology (AMP), the American Society of Clinical Oncology
(ASCO) and the College of American Pathologists (CAP).(26)
Statistical analysis. Statistical analysis was performed using
R studio 19.0 (RStudio, Boston, MA, USA) and IBM SPSS
Statistics 22.0 (SPSS, Chicago, IL, USA). The v2-test, the t-
test and Fisher’s exact test were used to analyze the associa-
tions of mutational status with clinical characteristics. The
association between driver gene alterations and ADC subtypes
was analyzed using a logistic model adjusted for age, gender
and smoking status. A two-tailed P-value of <0.05 was consid-
ered statistically significant.
Results
Patient characteristics. A total of 320 patients who underwent
either biopsy or surgery for lung cancer between June 2016
and December 2016 were enrolled for this study. Fourteen
patients were excluded because of incomplete clinicopathologi-
cal data (n = 6), non-lung primary tumor (n = 3) and insuffi-
cient tumor tissue (n = 5). The demographic and
histopathological features of the remaining 306 patients
included in the study are shown in Table 1. Regarding the his-
tologic subtype, 255 cases (83.3%) were lung ADC, 34
(11.1%) were SCC and 17 (5.6%) were lung cancer not other-
wise specified (NOS). The median age of the patients was
59 years (range: 21–82 years). A total of 144 (47.1%) patients
were female and 195 (63.7%) were never-smokers. Three (1%)
specimens were derived from tissues obtained at tumor biopsy,
and others were from surgically resected tissue. According to
the 7th edition of American Joint Committee on Cancer TNM
staging, 215 patients (70.3%) were classified as stage I and II,
and 91 patients (29.7%) as stage III and IV.
Genomic alterations. Both biopsy and surgical specimens
yielded sufficient DNA for hybrid capture-based NGS assay.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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The average depth of the target exceeded 696-fold, and more
than 98.86% of bases had at least 20-fold coverage (Fig. S1).
In the 306 samples tested, 845 individual genomic alterations
were found in 145 tumor-related genes, with a median of 2.8
alterations (range: 1–18) per sample. One or more genomic
alterations were identified in tumors from 92.8% (284 of 306)
of the patients, including 240 of the 255 (94.1%) individuals
with ADC, 32 of the 34 (94.1%) patients with SCC, and 12 of
the 17 (70.6%) patients with NOS. The distribution of driver
mutations is shown in Figure 1. The most frequently mutated
genes were EGFR (143 of 306, 46.7%), TP53 (65 of 306,
21.2%), ALK (37 of 306, 12.1%) and KRAS (31 of 306,
10.1%), which have all been reported as well-known driver
genes of lung cancer. The other frequently mutated genes
included EZH2 (8.8%), NOTCH1 (7.8%) and RBM10 (7.2%),
ESR1 (5.2%), RET (4.9%) and ERBB2 (4.5%). The majority of
SNV and InDels were in EGFR, TP53 and KRAS. Gene rear-
rangements most commonly involved ALK (3.3%, 10 of 306)
and ROS1 (1.3%, 4 of 306). Among the 10 ALK gene rear-
rangements and three MET amplifications detected using the
NGS assay, 12 (92.3%) showed consistent results with the con-
ventional test either by IHC or FISH, whereas one showed an
inconsistent result (Table S2).
Correlations between driver mutations and clinicopathological
characteristics. Correlations of genotype with clinicopathologi-
cal characteristics are listed in Table 2. The EGFR mutation
rate was significantly higher in women than in men (61.8% vs
33.3%, P < 0.001) and in patients with ADC than in those
with SCC and NOS (54.1% vs 8.8% and 11.8, P < 0.001). No
association was found between EGFR mutation status and the
patients’ age, smoking history and tumor stage. In contrast, the
KRAS mutation rate was significantly higher in men than in
women (16.0% vs 3.5%, P < 0.001) and in ever-smokers than
in never-smokers (17.1% vs 6.2%, P = 0.004). No association
was found between ALK rearrangement and clinicopathological
characteristics.
Driver mutation status in histopathologic subtypes of adeno-
carcinomas. Next, we aimed to investigate associations
between mutation status (EGFR and KRAS) and the new clas-
sification in our Asians cohort. We excluded patients for whom
predominant histology subtype could not be determined (6 of
255, 2.4%) and those with metastatic lung adenocarcinomas
Table 1. Clinicopathological characteristics of studied patients
Characteristic Number (%)
Gender
Male 162 52.9
Female 144 47.1
Age
Median 59
Range 21–82
Smoker
Never 195 63.7
Ever 111 36.3
Clinical stage
I & II 215 70.3
III & IV 91 29.7
Histology type
Adenocarcinoma 255 83.3
Squamous cell carcinoma 34 11.1
NOS 17 5.6
NOS, not otherwise specified.
Fig. 1. Significantly mutated genes and clinicopathological features of 306 patients with lung cancer tumors. Figure shows genes mutated in at
least 3% of the patients. Each column represents the cancer profile in one patient. Samples were sorted by tumor histology subtype, gender,
smoking history, and tumor stage distinguished by color. ADC, adenocarcinoma; INDEL, short insertions and deletions; NOS, not otherwise speci-
fied; SCC, squamous cell carcinoma; SNV, single nucleotide variations.
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(14 of 255, 5.5%). The histopathologic assessment according
to the IASLC/ATS/ERS classification showed that 9 (3.8%)
were AIS, 32 (13.6%) were MIA, 111 (47.2%) were acinar
predominant, 17 (7.2%) were lepidic predominant, 25 (10.6%)
were papillary predominant, 10 (4.3%) were micropapillary
predominant, 26 (11.1%) were solid predominant and 5 (2.1%)
were IMA.
EGFR mutations were positively correlated with acinar pre-
dominant tumors (P = 0.001) and negatively correlated with
solid predominant tumors (P = 0.023) (Table 3). Among the
235 cases, the frequency of EGFR mutation in the cases of
AIS, MIA, acinar predominant, lepidic predominant, papillary
predominant, micropapillary predominant, solid predominant
and IMA was 33.3%, 50.0%, 67.6%, 64.7%, 64.0%, 20.0%,
26.9% and 0%, respectively (Fig. 2).
KRAS mutations were most prevalent in IMA (60.0%), fol-
lowed by micropapillary predominant (20.0%), solid predomi-
nant (15.4%), lepidic predominant (11.8%), AIS (11.1%),
acinar predominant (7.2%), papillary predominant (4.0%) and
MIA (0%) (Fig. 2). The frequency of KRAS mutations was
positively correlated with IMA (P = 0.013) (Table 3).
Comparison between East Asians and Caucasians. To compare
the frequency of driver mutations of ADC between East Asians
and Caucasians, we obtained all the available ADC cases
(501) from The Cancer Genome Atlas (TCGA) dataset. Nota-
ble differences from TCGA data included EGFR (54.5% vs
15.0%, P < 0.001), KRAS (9.8% vs 33.7%; P < 0.001), TP53
(21.2% vs 54.1%, P < 0.001), ALK (10.2% vs 5.8%,
P = 0.027), EZH2 (9.4% vs 2.2%, P < 0.001), ERBB2 (5.5%
vs 2.4%, P = 0.027), MGA (3.5% vs 7.6%, P = 0.029), MYCN
(3.1% vs 1.0%, P = 0.032), NPM1 (3.5% vs 1.0%, P = 0.015),
BRAF (3.9% vs 8.4%, P = 0.022), SKT11 (3.1% vs 16.6%,
P < 0.001), PDGFRA (2.7% vs 7.0%, P = 0.016), NF1 (2.7%
vs 11.6%, P < 0.001) and ERBB4 (2.4% vs 8.4%, P = 0.001).
The full comparison of selected gene alteration frequencies
between two cohorts is depicted in Figure 3a and Table 4.
For EGFR mutation, missense mutation in exon 21 was
more frequently observed in East Asians (57.6% vs 37.3%,
P = 0.005), and exon 18 missense mutation (1.4% vs 8.0%,
P = 0.016) and mutations in exon 20 (1.4% vs 10.7%, P =
0.002) were more frequently observed in Caucasians. No sta-
tistically significant differences are observed in deletion and
insertions in exon 19 (39.6 vs 41.3%) and T790M on exon 20
(0.7% vs 2.7%). For KRAS mutation, comparing to Caucasians,
statistically significant differences were found in G12D in
Table 2. Correlation of EGFR and KRAS mutations and ALK rearrangements with clinicopathological features
Features
EGFR mutation KRAS mutation ALK gene rearrangement
Wild type (%) Mutant (%) P† value Wild type (%) Mutant (%) P† value Wild type (%) Mutant (%) P† value
Gender
Male 108 (66.7) 54 (33.3) <0.001 136 (84.0) 26 (16.0) <0.001 158 (97.5) 4 (2.5) 0.525
Female 55 (38.2) 89 (61.8) 139 (96.5) 5 (3.5) 138 (95.8) 6 (4.1)
Age
Mean (SD) 57.7 (11.8) 57.6 (10.4) 0.963 57.4 (11.5) 60.3 (6.8) 0.045 57.8 (11.1) 54.1 (11.2) 0.332
Smoking history
Never 83 (42.6) 112 (57.4) 0.318 183 (93.8) 12 (6.2) 0.004 189 (96.9) 6 (3.1) 1.000
Ever 40 (36.0) 71 (64.0) 92 (82.9) 19 (17.1) 107 (96.4) 4 (3.6)
Stage
I & II 109 (50.7) 106 (49.3) 0.207 197 (91.6) 18 (8.4) 0.174 211 (98.1) 4 (1.9) 0.070
III & IV 54 (59.3) 37 (40.7) 78 (85.7) 13 (14.3) 85 (93.4) 6 (6.6)
Histology type
ADC 117 (45.9) 138 (54.1) <0.001 231 (90.6) 24 (9.4) 0.359 247 (96.9) 8 (3.1) 0.333
SCC 31 (91.2) 3 (8.8) 29 (85.3) 5 (14.7) 32 (94.1) 2 (5.9)
†v2-test or Fisher’s exact test as appropriate. ADC, adenocarcinoma; SCC, squamous cell carcinoma.
Table 3. Correlation of EGFR and KRAS with histopathologic
subtypes of new adenocarcinoma classification
Features
EGFR mutation KRAS mutation
Wild type
(%)
Mutant
(%)
P†
Wild type
(%)
Mutant
(%)
P†
AIS 6 (66.7) 3 (33.3) 0.148 8 (88.9) 1 (11.1) 0.255
MIA 16 (50.0) 16 (50.0) 0.250 32 (100.0) 0 (0) 0.998
Acinar 36 (32.4) 75 (67.6) 0.001 103 (92.8) 8 (7.2) 0.446
Lepidic 6 (35.3) 11 (64.7) 0.517 15 (88.2) 2 (11.8) 0.637
Papillary 9 (36.0) 16 (64.0) 0.313 24 (96.0) 1 (4.0) 0.347
MP 8 (80.0) 2 (20.0) 0.210 8 (80.0) 2 (20.0) 0.554
Solid 19 (73.1) 7 (26.9) 0.023 22 (84.6) 4 (15.4) 0.723
IMA 5 (100.0) 0 (0.0) 0.999 2 (40.0) 3 (60.0) 0.013
†Logistic model adjusted for age, gender and smoking status. AIS,
adenocarcinoma in situ; IMA, invasive mucinous adenocarcinoma;
MIA, minimally invasive adenocarcinoma; MP, micropapillary adeno-
carcinoma.
Fig. 2. Gene mutation detection rates for each histological subtype
of adenocarcinoma (ADC). AIS, adenocarcinoma in situ; IMA, invasive
mucinous adenocarcinoma; MIA, minimally invasive adenocarcinoma;
MP, Micropapillary adenocarcinoma.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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Asians (28.0% vs 10.1%, P = 0.011) and in Q61H (16.0% vs
0.6%, P < 0.001).
Clinically relevant genomic alterations. Based on the recent
guidelines of NCCN, AMP, ASCO, and CAP, clinically relevant
genomic alterations were identified in 191 (62%) patients
(Table 5). Among the 255 patients with ADC, 174 (68%) har-
bored an actionable alteration, whereas only 13 (38%) of the 34
patients with SCC did so. As shown in Table 5, the clinically
relevant alterations with level I included EGFR mutations (140,
45.8%), KRAS mutations (31, 10.1%), ALK rearrangements (10,
Fig. 3. Comparison of selected gene mutations in adenocarcinoma (ADC) between East Asians with Caucasians. (a) Comparison of selected gene
alteration frequencies in East Asian and TCGA cohorts. Selected gene mutated in at least 3% of the East Asians cohort. (b) Gene mutation detec-
tion rates for EGFR in East Asian cohort. (c) Gene mutation detection rates for EGFR in TCGA. EGFR exon 18 mutations shown in green font;
EGFR exon 19 mutations shown in blue font; EGFR exon 20 mutations shown in red font; EGFR exon 21 mutations shown in black font. (d) Gene
mutation detection rates for KRAS in East Asian cohort. (e) Gene mutation detection rates for KRAS in TCGA. TCGA, The Cancer Genome Atlas.
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3.3%) and ROS1 rearrangements (4, 1.3%). EGFR was the most
frequently mutated gene and mutations in EGFR were detected
in 46.7% (143 of 306) of the cases. Exon 19 deletions (54 of
143, 37.8%) and exon 21 L858R point mutation (79 of 143,
55.2%) accounted for 93.0% of all the detected EGFR muta-
tions. Other EGFR mutations included G719X (n = 2) on
exon 18, M766_A767insASV (n = 1), D770_N771insSVD
(n = 1) and T790M (n = 1) on exon 20, L861Q (n = 2) on
exon 21, and gene amplifications (n = 3).
In addition, patients with level II genomic alterations, for
which targeted therapy could be considered in phase II/III clin-
ical trials, were found in five patients (1.6%). These included
the following alterations: NRAS mutation (n = 1), MET ampli-
fication (n = 3) and ERBB2 insertion (n = 1) (Table 5).
Finally, there were eight patients with level III and IV geno-
mic alterations, including BRAF V600E mutation (n = 2),
PIK3CA H1047X mutation (n = 3) and EGFR amplification
(n = 3) (Table 5), which indicate sensitivity or resistance to
therapies approved by the FDA or to those included in the pro-
fessional guidelines for other cancers. We also found drivers
in two genes in seven tumors (2.2%). Gene pairings and speci-
fic mutations for these patients are presented in Table S3.
Discussion
Lung cancer is the most common cancer and the leading cause
of cancer-related deaths in China. Approximately 700 000 new
cases of lung cancer are reported every year in China. Over
300 000 patients with advanced non-squamous NSCLC are
expected to be screened for EGFR mutations and ALK rear-
rangements according to current guidelines.(39,40) In the present
study, we successfully used a well-validated NGS assay to per-
form comprehensive genomic profiling on tumor specimens
from 306 Chinese lung cancer patients. To our knowledge, this
study is the largest in China to demonstrate the successful
implementation of routine molecular profiling of patients with
NSCLC using targeted NGS. We found that targeted NGS is a
cost-effective and rapid platform (with a TAT of 6 days). It is
feasible within the clinical workflow and enabled the detection
of at least one clinically relevant genomic alterations in 62%
of the analyses.
Asian people have unique clinical characteristics and tumor
histology and show different prevalence of oncogenic muta-
tions.(22) In this study, EGFR mutations were more common in
women and in patients with ADC, especially with acinar pre-
dominant tumors, but less frequent in patients with solid pre-
dominant ADC. In addition, it is not correlated to age, smoking
history and tumor stage. The KRAS mutation rate was also more
common in men, ever-smokers and patients with IMA. Upon
comparison of driver gene mutations of lung adenocarcinoma
with the TCGA dataset, we found that EGFR was mutated at a
much higher frequency in our cohort than in Caucasians. In con-
trast, KRAS, the second most commonly mutated gene in Cau-
casians, was only found in 9.8% of the Chinese ADC patients in
our study. Furthermore, the subtype distribution of the EGFR
and KRAS mutation was different from ethnicity. EGFR muta-
tion in exon 21, KRAS G12D and Q61H was more frequently
observed in Asians compared to Caucasians. It might be helpful
to determine whether mutation phenotypes are correlated with
sensitivity or resistance to EGFR-TKI therapy.
Another purpose of the present study was to demonstrate
that our comprehensive genomic profiling assay based on a
hybrid-capture NGS approach could be used to guide therapy
decisions and patient enrolment into clinical trials. Screening
for somatic mutations in EGFR and KRAS and rearrangements
in ALK is now an established component of routine diagnostic
practice in Chinese hospitals.(41) However, single-gene PCR
and FISH assays with limited sensitivity are more often used
than NGS platforms, which are capable of identifying various
alterations in multiple genes from a single tumor sample. In
our study, we found that 22 (7.2%) patients harbored clinically
actionable alterations that were not previously discovered in
the routine clinical test, which could enable clinicians to select
more targeted treatments. The majority of these alterations
were recurrent gene mutations or rearrangements involving
PIK3CA, ROS1 and MET. The presence of mutations in
PIK3CA and MET amplifications has been reported to possibly
lead to EGFR TKI resistance. In our cohort, actionable geno-
mic alterations that were potentially treatable with therapeutic
agents were identified in 57% of all lung tumors and in 62%
of lung ADC within nine genes (KRAS, EGFR, ALK, ROS1,
ERBB2, BRAF, PIK3CA, MET and NRAS). A similar study
previously conducted by The Lung Cancer Mutation Consor-
tium (LCMC) showed that actionable drivers were detected in
64% (466 in 733) of lung ADC in 10 genes (KRAS, EGFR,
ALK, ERBB2, BRAF, PIK3CA, MET, NRAS, MEK1 and
AKT1).(19) In comparison with the LCMC study, our study had
a cohort with a higher actionable mutation rate in EGFR and
lower KRAS and ALK mutation rate. No significant difference
was observed in BRAF, ERBB2, PIK3CA, NRAS and MET
mutation status.
Table 4. Comparison of driver gene mutations of lung
adenocarcinoma between East Asian patients and the Caucasian
cohort in TCGA dataset
East Asians (255) Caucasians (501)
Pa
Wild type
(%)
Mutant
(%)
Wild type
(%)
Mutant
(%)
EGFR 139 (54.5) 116 (45.5) 424 (84.6) 77 (15.4) <0.001
KRAS 25 (9.8) 230 (90.2) 169 (33.7) 332 (66.3) <0.001
TP53 201 (78.8) 54 (21.2) 230 (45.9) 271 (54.1) <0.001
ALK 229 (89.8) 26 (10.2) 472 (94.2) 29 (5.8) 0.027
EZH2 231 (90.6) 24 (9.4) 490 (97.8) 11 (2.2) <0.001
NOTCH1 238 (93.3) 17 (6.7) 477 (95.2) 24 (4.8) 0.282
RBM10 234 (91.8) 21 (8.2) 467 (93.2) 34 (6.8) 0.468
ESR1 243 (95.3) 12 (4.7) 490 (97.8) 11 (2.2) 0.057
RET 246 (96.5) 9 (3.5) 481 (96.0) 20 (4.0) 0.754
ERBB2 241 (94.5) 14 (5.5) 489 (97.6) 12 (2.4) 0.027
ARID1A 244 (95.7) 11 (4.3) 469 (93.6) 32 (6.4) 0.245
MGA 246 (96.5) 9 (3.5) 463 (92.4) 38 (13.6) 0.029
PIK3CA 246 (96.5) 9 (3.5) 472 (94.2) 29 (5.8) 0.179
APC 246 (96.5) 9 (3.5) 479 (95.6) 22 (4.4) 0.572
MYCN 247 (96.9) 8 (3.1) 496 (99.0) 5 (1.0) 0.032
NPM1 246 (96.5) 9 (3.5) 496 (99.0) 5 (1.0) 0.015
BRAF 245 (96.1) 10 (3.9) 459 (91.6) 42 (8.4) 0.022
SKT11 247 (96.9) 8 (3.1) 418 (83.4) 83 (16.6) <0.001
ROS1 248 (97.3) 7 (2.7) 478 (95.4) 23 (4.6) 0.197
PDGFRA 248 (97.3) 7 (2.7) 466 (93.0) 35 (7.0) 0.016
NF1 248 (97.3) 7 (2.7) 443 (88.4) 58 (11.6) <0.001
FLT4 249 (97.6) 6 (2.4) 482 (96.2) 19 (3.8) 0.295
NFE2L2 252 (98.8) 3 (1.2) 489 (97.6) 12 (2.4) 0.256
MTOR 246 (96.5) 9 (3.5) 476 (95.0) 25 (5.0) 0.360
ERBB4 249 (97.6) 6 (2.4) 459 (91.6) 42 (8.4) 0.001
DDR2 248 (97.3) 7 (2.7) 484 (96.6) 17 (3.4) 0.631
aChi-square test was used.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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The present study has a few limitations. First, it is a single-
center analysis of the genomic profiling of lung cancer, which
may not be representative of the overall situation in China. Sec-
ond, although there was a higher EGFR mutation rate in the Chi-
nese population, the majority of patients, including early or
advanced stage patients, were still being treated with platinum
therapy, mainly because TKI agents are not covered by insur-
ance. Therefore, the clinical outcome information was available
only for a relatively small subset of cases. In the future, prospec-
tive randomized clinical trials are needed to confirm the observa-
tions described in the present study.
In the present study, we revealed the similarities and differ-
ences in the mutational features of NSCLC between Chinese
and Caucasian populations. We demonstrated the successful
application of the hybrid capture-based NGS approach for per-
forming comprehensive genomic profiling in Chinese lung can-
cer patients. Given the increased availability of various
targeted therapies, our findings have implications for cancer
translational research and management.
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